The UNITI-Jr trial assessed the safety and efficacy of ustekinumab in paediatric patients over 52 weeks. Results showed 52.1% of patients achieved clinical remission after 8 weeks of treatment, with ...

Stelara is a monoclonal antibody designed to block the activity ... Agency’s human medicines committee and was based on positive results from the late-stage UNITI-Jr trial, in which 52.1% of ...

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

LITTLE ROCK, Ark., April 23, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its appointment of John Harrobin as President of Kinetic ...

LITTLE ROCK, Ark., April 17, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced that its Board of Directors (the “Board”) has nominated ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

Jennifer Banner Recognized for Her 10 Years of Dedicated Service LITTLE ROCK, Ark., April 17, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. ("Uniti” or the "Company”) (Nasdaq: UNIT) today announced that ...

LITTLE ROCK, Ark., April 23, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. ("Uniti” or the "Company”) (Nasdaq: UNIT) today announced its appointment of John Harrobin as President of Kinetic, effective ...

LITTLE ROCK, Ark. - Uniti Group Inc. (NASDAQ:UNIT), a real estate investment trust specializing in communications infrastructure with a market capitalization of $1.28 billion and annual revenue of ...

Among the most significant milestones was the launch of ustekinumab biosimilars following the loss of exclusivity for Stelara. This expansion has played a pivotal role in fostering market ...